Bovine Parainfluenza Virus Type 3 (BPIV3) Fusion and Hemagglutinin-Neuraminidase Glycoproteins Make an Important Contribution to the Restricted Replication of BPIV3 in Primates

Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Journal of Virology (Impact Factor: 4.44). 11/2000; 74(19):8922-9. DOI: 10.1128/JVI.74.19.8922-8929.2000
Source: PubMed


This study examines the contribution of the fusion (F) and hemagglutinin-neuraminidase (HN) glycoprotein genes of bovine parainfluenza virus type 3 (BPIV3) to its restricted replication in the respiratory tract of nonhuman primates. A chimeric recombinant human parainfluenza type 3 virus (HPIV3) containing BPIV3 F and HN glycoprotein genes in place of its own and the reciprocal recombinant consisting of BPIV3 bearing the HPIV3 F and HN genes (rBPIV3-F(H)HN(H)) were generated to assess the effect of glycoprotein substitution on replication of HPIV3 and BPIV3 in the upper and lower respiratory tract of rhesus monkeys. The chimeric viruses were readily recovered and replicated in simian LLC-MK2 cells to a level comparable to that of their parental viruses, suggesting that the heterologous glycoproteins were compatible with the PIV3 internal proteins. HPIV3 bearing the BPIV3 F and HN genes was restricted in replication in rhesus monkeys to a level similar to that of its BPIV3 parent virus, indicating that the glycoprotein genes of BPIV3 are major determinants of its host range restriction of replication in rhesus monkeys. rBPIV3-F(H)HN(H) replicated in rhesus monkeys to a level intermediate between that of HPIV3 and BPIV3. This observation indicates that the F and HN genes make a significant contribution to the overall attenuation of BPIV3 for rhesus monkeys. Furthermore, it shows that BPIV3 sequences outside the F and HN region also contribute to the attenuation phenotype in primates, a finding consistent with the previous demonstration that the nucleoprotein coding sequence of BPIV3 is a determinant of its attenuation for primates. Despite its restricted replication in the respiratory tract of rhesus monkeys, rBPIV3-F(H)HN(H) conferred a level of protection against challenge with HPIV3 that was indistinguishable from that induced by previous infection with wild-type HPIV3. The usefulness of rBPIV3-F(H)HN(H) as a vaccine candidate against HPIV3 and as a vector for other viral antigens is discussed.

Download full-text


Available from: Mario Skiadopoulos, Mar 28, 2014
  • Source
    • "These strains elicited an improved antibody response and, in monkeys , protected against HPIV-3 infection. Two of the chimeric viruses, one containing the HN gene from the bovine virus in a human virus background and the other containing the F and HN glycoprotein genes from the human virus in the bovine virus background are now viewed as the strongest vaccine candidates for human trials [96] [97] [98]. The latter candidate combines the host range restriction of BPIV-3 with the major antigenic determinants of HPIV-3, permitting efficient replication in vitro (which is beneficial for vaccine development) along with host range phenotype and excellent antigenicity . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Respiratory syncytial virus (RSV), the recently identified human metapneumovirus (HMPV), and the human parainfluenza viruses (HPIVs), cause most cases of childhood croup, bronchiolitis, and pneumonia. Influenza virus also causes a significant burden of disease in young children, although its significance in children was not fully recognized until recently. This article discusses pathogens that have been studied for several decades, including RSV and HPIVs, and also explores the newly identified viral pathogens HMPV and human coronavirus NL63. The escalating rate of emergence of new infectious agents, fortunately meeting with equally rapid advancements in molecular methods of surveillance and pathogen discovery, means that new organisms will soon be added to the list. A section on therapies for bronchiolitis addresses the final common pathways that can result from infection with diverse pathogens, highlighting the mechanisms that may be amenable to therapeutic approaches. The article concludes with a discussion of the overarching impact of new diagnostic strategies.
    Preview · Article · Nov 2006 · Pediatric Clinics of North America
  • Source
    • "The attenuation phenotype of BPIV3 has been characterized in detail, and its polygenic nature, based on a great number of host range mutations, should guarantee stability following replication in vivo and should provide for added safety in a live-attenuated vaccine (Skiadopoulos et al., 2003). A recombinant version of BPIV3 was generated, and antigenic chimeric viruses in which the HN and F antigens of BPIV3 are replaced by those of HPIV3 (rB/HPIV3) are now available as vectors (Schmidt et al., 2000). rB/HPIV3 viruses replicate to high titer (10 8.0 TCID 50 /ml) in vitro and should be infectious in humans at 10 5.0 TCID 50 , thus economical to produce. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Respiratory Syncytial Virus 2003 symposium took place from 8th-11th November 2003 in Stone Mountain, Georgia, and brought together more than 200 international investigators engaged in RSV research. RSV biology, pathogenesis, and clinical data, as well as RSV vaccines and antivirals, were addressed in the meeting, and this review will aim to briefly summarize and discuss the implications of new findings. The meeting also served as the inauguration of the Robert M. Chanock Award for lifetime achievement in RSV research, an award named in honor of the person who started the field of RSV research by recovering the first human RS virus from infants with severe bronchiolitis in 1956.
    Full-text · Article · Dec 2004 · Virus Research
  • Source
    • "Both recombinant and biological bPIV-3 showed titre reductions of 25-and 63-fold in the URT, respectively, and 79-fold reductions in the LRT. b/hPIV-3 displayed an intermediate attenuation phenotype between the attenuated bPIV-3 and the non-attenuated hPIV-3, which indicated that some attenuation determinants are located in the F and HN genes, as suggested previously (Schmidt et al., 2000). Whether this decrease of attenuation of b/hPIV-3 in rhesus monkeys will affect its safety profile in humans and whether insertion of additional viral genes encoding protective antigens from other respiratory viruses will compensate for the decreased attenuation of this vector remains to be determined. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Restricted replication in the respiratory tract of rhesus monkeys is an intrinsic property of bovine parainfluenza virus type 3 (bPIV-3) strains. This host range phenotype of bPIV-3 has been utilized as a marker to evaluate the attenuation of bPIV-3 vaccines for human use. Two safety, immunogenicity and efficacy studies in primates evaluated and compared three human parainfluenza virus type 3 (hPIV-3) vaccine candidates: biologically derived bPIV-3, a plasmid-derived bPIV-3 (r-bPIV-3) and a chimeric bovine/human PIV-3 (b/hPIV-3). These studies also examined the feasibility of substituting Vero cells, cultured in the presence or absence of foetal bovine serum, for foetal rhesus lung-2 (FRhL-2) cells as the tissue culture substrate for the production of bPIV-3 vaccine. The results demonstrated that (i) Vero cell-produced bPIV-3 was as attenuated, immunogenic and efficacious as bPIV-3 vaccine grown in FRhL-2 cells, (ii) plasmid-derived bPIV-3 was as attenuated, immunogenic and efficacious as the biologically derived bPIV-3 and (iii) the b/hPIV-3 chimera displayed an intermediate attenuation phenotype and protected animals completely from hPIV-3 challenge. These results support the use of bPIV-3 vaccines propagated in Vero cells in human clinical trials and the use of b/hPIV-3 as a virus vaccine vector to express foreign viral antigens.
    Full-text · Article · Dec 2003 · Journal of General Virology
Show more